- Home
- DAVE vs AUPH Comparison
DAVE vs AUPH Comparison
Compare DAVE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- AUPH
- Stock Information
- Founded
- DAVE 2017
- AUPH 1993
- Country
- DAVE United States
- AUPH Canada
- Employees
- DAVE N/A
- AUPH N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- AUPH Health Care
- Exchange
- DAVE Nasdaq
- AUPH Nasdaq
- Market Cap
- DAVE 1.1B
- AUPH 999.8M
- IPO Year
- DAVE N/A
- AUPH 1999
- Fundamental
- Price
- DAVE $84.27
- AUPH $7.75
- Analyst Decision
- DAVE Strong Buy
- AUPH Strong Buy
- Analyst Count
- DAVE 7
- AUPH 2
- Target Price
- DAVE $117.71
- AUPH $11.50
- AVG Volume (30 Days)
- DAVE 420.4K
- AUPH 1.3M
- Earning Date
- DAVE 05-06-2025
- AUPH 05-01-2025
- Dividend Yield
- DAVE N/A
- AUPH N/A
- EPS Growth
- DAVE N/A
- AUPH N/A
- EPS
- DAVE 4.19
- AUPH 0.04
- Revenue
- DAVE $347,076,000.00
- AUPH $235,133,000.00
- Revenue This Year
- DAVE $24.29
- AUPH $11.86
- Revenue Next Year
- DAVE $18.11
- AUPH $24.96
- P/E Ratio
- DAVE $20.11
- AUPH $193.75
- Revenue Growth
- DAVE 33.96
- AUPH 33.97
- 52 Week Low
- DAVE $28.31
- AUPH $4.71
- 52 Week High
- DAVE $125.00
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- DAVE 49.07
- AUPH 46.63
- Support Level
- DAVE $79.85
- AUPH $7.59
- Resistance Level
- DAVE $87.65
- AUPH $7.83
- Average True Range (ATR)
- DAVE 7.08
- AUPH 0.35
- MACD
- DAVE 0.69
- AUPH -0.02
- Stochastic Oscillator
- DAVE 72.91
- AUPH 65.84
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.